News | PET Imaging | March 03, 2016

Patient Enrollment Opens For Largest Brain Amyloid Scanning Research Study

IDEAS Study offers reimbursement for PET imaging to help clarify diagnosis of dementia in patients in whom cause is uncertain

Alzheimer's disease, IDEAS study, patient enrollment open, amyloid PET scan

March 3, 2016 — Participating dementia specialists may now enroll patients in the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study at IDEAS-Study.org. Primary care and other doctors not taking part in the IDEAS Study are encouraged to refer eligible patients to participating physicians.

The IDEAS Study will follow more than 18,000 Medicare beneficiaries to determine the clinical value of a brain positron emission tomography (PET) scan to detect the hallmark brain amyloid accumulation of Alzheimer's disease in diagnosing and managing treatment of patients age 65 and older with mild cognitive impairment (MCI) or dementia of uncertain cause. Information from this scan can help exclude underlying Alzheimer's disease, and may help guide patient management.

"We are excited that approved physicians may begin registering patients for the IDEAS Study. We anticipate that results from the study will greatly inform future treatment and coverage decisions that can benefit countless Americans and others around the world," said Gil D. Rabinovici, M.D., IDEAS Study principal investigator and associate professor of neurology at the University of California, San Francisco.

Board-certified neurologists, psychiatrists and geriatric medicine physicians interested in enrolling eligible patients in the IDEAS Study, along with PET facilities that would like to join the study as imaging sites, may apply for participation online using the register/login portal. Participating physicians may enroll eligible patients using the same portal. Background on the study, requirements for participation and a set of frequently asked questions are available on the IDEAS website.

"The IDEAS Study will provide the evidence needed to demonstrate the utility of amyloid PET imaging in a clinical setting and for future decision making about insurance coverage for what we believe to be an important diagnostic tool," said Maria Carrillo, Ph.D., Alzheimer's Association chief science officer and IDEAS Study co-chair. "A swift and accurate diagnosis has a huge impact on access to Alzheimer's treatments, eligibility for research trials, plus much-needed support and information services."

The IDEAS Study will not directly recruit patients. Participants must instead be referred into the study by dementia specialists. Dementia specialists will enroll patients whose cases meet the study enrollment criteria and refer them for an amyloid PET scan. Amyloid PET scans will be performed and interpreted by a nuclear medicine physician or radiologist, with results provided to the ordering physician for disclosure to the patient and to support further diagnostic decisions. Scan results and diagnosis will be captured for the study.

Participating PET facilities and interpreting physicians will be reimbursed for the scans under the Centers for Medicare & Medicaid Services (CMS) Coverage with Evidence Development (CED) policy that requires research study participation as a condition of Medicare payment. This is currently the only way a brain amyloid PET scan will be covered for Medicare beneficiaries.

The IDEAS Study is led by the Alzheimer's Association and managed by the American College of Radiology (ACR) and American College of Radiology Imaging Network (ACRIN).

For more information: www.ideas-study.org

Related Content

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Treatment Planning | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
Bay Labs Announces New Echocardiography Guidance Software Data at ASE 2019 Scientific Sessions
News | Cardiovascular Ultrasound | June 20, 2019
Bay Labs announced that new data on the company’s first-of-its-kind deep learning investigational guidance software...
Third FDA Clearance Announced for Zebra-Med's AI Solution for Brain Bleed Alerts
Technology | Artificial Intelligence | June 19, 2019
Zebra Medical Vision announced it has received its third U.S. Food and Drug Administration (FDA) 510(k) clearance for...
United Imaging Announces First U.S. Clinical Install of uMI 550 Digital PET/CT System
News | PET-CT | June 19, 2019
United Imaging announced the first U.S. clinical installation of the uMI 550 Digital positron emission tomography/...
LVivo EF Comparable to MRI, Contrast Echo in Assessing Ejection Fraction
News | Cardiovascular Ultrasound | June 19, 2019
DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
SyMRI Software Receives FDA Clearance for Use With Siemens MRI Systems
Technology | Magnetic Resonance Imaging (MRI) | June 14, 2019
SyntheticMR announced U.S. Food and Drug Administration (FDA) clearance for clinical use of its SyMRI Image and SyMRI...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...